ClinicalTrials.gg
CompletedNCT03337672Updated Jan 9, 2019

Comparison of Dexmedetomidine and Midazolam for Prevention of Emergence Delirium in Children

An interventional study of Dexmedetomidine and Midazolam in Tonsillitis, sponsored by Eunah Cho, MD. Completed at 1 site in Korea, Republic of. Open to participants aged 24 Months to 12 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-01-09.

Sponsored by Eunah Cho, MD · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
24 Months to 12 Years
Sex
All
01

Study summary

Emergence delirium is a common complication in children after anesthesia. The incidence of emergence delirium is reported upto 50%. Prevention of emergence delirium in children is important not only for the patient safety but also for the satisfaction of the parents. Midazolam is the most commonly used medications for prevention of emergence delirium. However, it might lead to delayed awakening from anesthesia and respiratory depression. In this study, the investigators will evaluate whether dexmedetomidine can be effectively and safely administered for prevention of emergence delirium in children compared to midazolam.

Read the detailed description

In this study, seventy patients scheduled for elective tonsillectomy aged from 24 months to 12 years old Anesthesiologists physical status (ASA) class 1 and 2 will be enrolled. The sample size was calculated based on the former study with a type 1 error estimate of 0.05 at 80% power. The proportion in dexmedetomidine group (group D) was assumed to be 0.4 and the proportion in midazolam group (group M) was 0.1. Considering the drop-out rate of 10%, seventy patients in total were needed.The patients will randomly be allocated into the group D or the group M. The group D will receive dexmedetomidine0.3mcg/kg mixed with 0.9% normal saline, 10mL in total. The group M will receive 0.03mg/kg of midazolam mixed with 0.9% normal saline, 10mL in total. Randomization and drug administration will be done by a single anesthesiologist. Assessment of the patient will be done by another anesthesiologist blinded by the group. Five minutes before the end of the surgery, the study drug will be slowly infused for 5 minutes. In the postanesthesia circuit unit (PACU), presence of emergence delirium will be assessed. The emergence delirium will be assessed by the four-point agitation scale. (1 = calm, 2 = not calm but gould be easily calmed, 3 = not easily calmed, moderately agitated or restless, and 4 = combative, exited or disoriented.) Patients with score 3 and 4 will be diagnosed as emergence delirium and treated with intravenous fentanyl 1mcg/kg. Severity of emergence delirium will be assessed with the pediatric anesthesia emergence delirium scale after 10 mins on arrival of PACU. Pain wil be scored by 5-point scale (0 = no pain, 5 = severe pain ever). Time from discontinuation of anesthetic gas to extubate will be recorded. The data will be compared between the groups by the independent t-test or Mann-Whitney test for the continuous variables. Chi-square test or Fisher's exact test will be used for the categorial variables.

02

Conditions studied

  • Tonsillitis

Browse trials for

03

In context

Tonsillitis

103 studies on the registry are indexed under Tonsillitis; 12 are open to participants now.

This study's enrollment of 70 is below the median of 100 across 87 interventional studies indexed under Tonsillitis.

Browse Tonsillitis studies →

Lead sponsor

Eunah Cho, MD is the lead sponsor of 8 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
24 Months to 12 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients undergoing elective tonsillectomy under general anesthesia
  • physical status 1,2
  • aged from 24 months to 12 years old
  • obtaining written

Exclusion criteria

Exclusion Criteria:

  • known history of allergy to dexmedetomidine or midazolam
  • renal impairment
  • hepatic impairment
  • long syndrome
  • developmental disorder
  • congenital disorder
  • neurologic disorder
  • psychogenic disorder
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    Dexmedetomidine group

    Subjects who receive dexmedetomidine for prevention of emergence delirium

    Drug: Dexmedetomidine

  • Active comparator
    Midazolam group

    Subjects who receive midazolam for prevention of emergence delirium

    Drug: Midazolam

Interventions

  • Intravenous dexmedetomidine 0.3mcg/kg is slowly infused at 5 minutes before the end of surgery

  • Intravenous dexmedetomidine 0.03mg/kg is slowly infused at 5 minutes before the end of surgery

06

What researchers measure

Primary outcomes

  1. Presence of Emergence Delirium (ED)

    During the PACU stay, the patients will be assessed whether the emergence delirium (ED) occurred. It is defined as ED, if the highest score is more than 3 points after five time point measurements by the four-point agitation scale (1=calm, 2=not calm but easily calmed, 3=not easily calmed, moderately agitated, and 4=combative, excited, disoriented). The five time points are the 0 minute, 5 minutes, 10 minutes, 15 minutes and 20 minutes after arrival at the PACU.

    Time frame: 0 minute, 5 minutes, 10 minutes, 15 minutes and 20 minutes after arrival at the PACU

Secondary outcomes

  1. Severity of Emergence Delirium

    Patients will be scored using the pediatric anesthesia emergence delirium scale. This consists of 5 criteria, each of which is pointed from 0 to 5 according to the severity. Total score stands for the delirium severity.

    Time frame: 10 minutes after arrival at the PACU

  2. Emergence time

    Time from the discontinuation of the anesthetic gas to extubation.

    Time frame: 3 minutes after extubation

07

Study locations

1 site
  • Kangbuk Samsung Hospital
    Seoul, 03181, Korea, Republic of
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 9, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03337672
Lead sponsor
Eunah Cho, MD
Responsible party
Eunah Cho, MD (Clinical Assistant Professor, Kangbuk Samsung Hospital) — Sponsor-investigator
First posted
Nov 9, 2017
Start date
Dec 5, 2017
Primary completion
Dec 17, 2018
Completion
Dec 17, 2018
Last update
Jan 9, 2019

Study contacts

Eunah Cho, M.D.
principal investigator · Kangbuk Samsung Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexmedetomidine

Start the discussion